SGLT2 Inhibitor Drug that lowers blood sugar also reduces aging-related blood vessel dysfunction

Joseph · 2022-06-01T16:27:35.299Z

Drug that lowers blood sugar also reduces aging-related blood vessel dysfunction

Author: Eleanor Garth
Last updated: May 31, 2022

FDA-approved drug for type 2 diabetes prevented vascular constriction and stiffening in aging male mice.

Longevity.Technology - Latest News, Opinions, Analysis and Research – 31 May 22

Drug that lowers blood sugar also reduces aging-related blood vessel dysfunction

FDA-approved drug for type 2 diabetes may also may decrease blood vessel dysfunction associated with aging, according to new research.

Estimated reading time: 3 minutes

Joseph · 2022-06-01T18:23:26.376Z

A link to the mentioned study in the above article.

SGLT2 inhibition attenuates arterial dysfunction and decreases vascular F-actin content and expression of proteins associated with oxidative stress in aged mice

SpringerLink

SGLT2 inhibition attenuates arterial dysfunction and decreases vascular...

Aging of the vasculature is characterized by endothelial dysfunction and arterial stiffening, two key events in the pathogenesis of cardiovascular disease (CVD). Treatment with sodium glucose transporter 2 (SGLT2) inhibitors is now known to decrease...

desertshores · 2022-06-01T22:50:03.135Z

Fortunately, I chose to add empagliflozin10mg to my metformin because my fasting glucose levels have increased since I started taking rapamycin. I source from India because it is relatively cheap and less hassle than seeing my doctor and trying to convince him I need it.
I think I will up the dose to 20 mg. (For younger people please see your doctor)

Also if you are taking a “URINALYSIS, COMPLETE” test and take empagliflozin within 12 to 18 hrs before your test do not be surprised to find some glucose in your urine.
“Jardiance and other SGLT2 inhibitors increase excretion of glucose in urine and will cause positive urine glucose tests”
If you don’t know this you will say: WTF!

RapAdmin · 2022-06-01T23:03:42.900Z

More info see:

Canagliflozin - Another Top Anti-aging Drug

[CanagSm3] Canagliflozin: Significant Lifespan Extension Results in Male Mice Results of the National Institutes on Aging, ITP study Canagliflozin extends life span in genetically heterogeneous male but not female mice Increased median lifespan in the male mice by 14%, maximum extension of 9% But had no effect on the females Canagliflozin is in the class of drugs known as SGLT2 inhibitors. SGLT2 inhibitors have been commercially available for over 10 years and they are used commonly in patients with type 2 diabetes as it blocks the re-uptake of glucose so that more glucose is excreted in the urine. They affect the process in the kidney that deals with very high glucose levels without having much scope for causing toxicity, so are safe from causing hypoglycemia. While canagliflozin…